Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar 9:11:20.
doi: 10.1186/1471-2296-11-20.

Colorectal cancer screening using the faecal occult blood test (FOBt): a survey of GP attitudes and practices in the UK

Affiliations

Colorectal cancer screening using the faecal occult blood test (FOBt): a survey of GP attitudes and practices in the UK

Sarah Damery et al. BMC Fam Pract. .

Abstract

Background: Colorectal cancer (CRC) is the third most common cancer in the UK. Five-year survival rates are less than 50%, largely because of late diagnosis. Screening using faecal occult blood tests (FOBt) can detect bowel cancer at an earlier stage than symptomatic presentation, and has the potential to significantly decrease colorectal cancer mortality. However, uptake of screening is currently low, despite the introduction of the NHS Bowel Cancer Screening Programme (NHSBCSP), and it has been suggested that GP recommendations of screening can improve patient compliance. GP recommendation of CRC screening is argued to be affected by attitudes towards it, along with perceptions of its efficacy.

Methods: This paper presents the findings of a cross-sectional postal survey of GPs in the UK which aimed to investigate GPs' attitudes in relation to colorectal cancer screening and the use of FOBt in routine practice. An 'attitude' score was calculated, and binary logistic regression used to evaluate the association of socio-demographic and general practice attributes with attitudes towards CRC screening and FOBt.

Results: Of 3,191 GPs surveyed, 960 returned usable responses (response rate 30.7%). Positive attitudes were associated with personal experience of CRC screening and Asian or Asian British ethnicity. GPs from practices located in more deprived locations were also more likely to have positive attitudes towards FOBt and its recommendation to patients.

Conclusions: The success of population-based screening for CRC will largely be determined by GP attitudes and support, particularly with regard to FOBt. Previous research has implied that South Asian GPs are more likely to have negative attitudes towards FOBt screening, however, our research suggests that this is not a group requiring targeted interventions to increase their support for the NHSBCSP. Of the available CRC screening tests, GPs perceived FOBt to be the most appropriate for population-based screening.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Consort diagram detailing surveys mailed and returned.

Similar articles

Cited by

References

    1. Atkin WS. Impending or pending? The national bowel cancer screening programme. BMJ. 2006;332:742. doi: 10.1136/bmj.38797.494757.47. - DOI - PMC - PubMed
    1. Macaffee D, Gemmil E, Lund J. Colorectal cancer: current care, future innovations and economic considerations. Expert Rev Pharmacoeconomics Outcomes Res. 2006;6:195–206. doi: 10.1586/14737167.6.2.195. - DOI - PubMed
    1. Coleman M, Cooper N, Ellis L, Rachet B, Rasulo D, Shah A, Westlake S. One and five year relative survival for patients diagnosed in 1998-2004 in 'Spearhead' PCTs compared with those in the rest of England: 10 common cancers by sex. London: National Office of Statistics; 2008.
    1. Office of National Statistics. Mortality statistics: review of the Registrar General on deaths by cause, sex and age in England and Wales. 29. Vol. 2. London: Office of National Statistics; 2003.
    1. Berrino F, De Angelis R, Sant M, Rosso S, Lasota M, Coebergh J, Santaquilani M. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncology. 2007;8(9):773–783. doi: 10.1016/S1470-2045(07)70245-0. - DOI - PubMed

MeSH terms